New York-based Actinium Pharmaceuticals has begun enrolling patients in RADIANZ, a study to guide development of its actinium-225 (Ac-225) radiotherapy ATNM-400 in solid tumors beyond prostate cancer.
The study will include patients with non-small cell lung cancer or with breast, colorectal, pancreatic, or ovarian cancer whose disease has progressed on standard-of-care therapy. Participants will undergo PET imaging with zirconium-89 (Zr-89)-labeled barecetamab at time points up to two weeks. The study will assess biodistribution, tumor uptake, pharmacokinetics, and dosimetry across tumor types, according to the company.
ATNM-400 is an investigational antibody radioconjugate that pairs barecetamab, a monoclonal antibody targeting human epidermal growth factor receptor 3 (HER3), with Ac-225. The agent is in a first-in-human phase I study in metastatic castration-resistant prostate cancer.
For similar stories and updates, check out AuntMinnie’s Radiopharmaceutical Therapy Tracker.
